Select News Items featuring Valcreate
Zee Business | Rajesh Pherwani | June 26, 2026
The sharp fall in crude oil prices has brought markets back to where they were before the Iran conflict..
Business Today | Rajesh Pherwani | April 26, 2026
Days after semaglutide, the molecule behind blockbuster weight-loss drugs, went off patent in India, prices dropped sharply as multiple generic versions entered the market.
Money Control | Rajesh Pherwani | November 18, 2024
Valcreate Lifesciences & Specialty strategy was amongst the top-10 out-performers during the month of Oct-24 despite a weak market sentiment.
Money Control | Rajesh Pherwani | August 14, 2024
According to data from PMS Bazaar, Valcreate Investment Managers - Lifesciences and Specialty Opportunity Fund ranked first, with a return of 12.13 percent in July.
Business Today | Rajesh Pherwani | October 11, 2023
Worries about essential drug shortages arise due to conflict-related impacts on trade routes
Business Today | Rajesh Pherwani | August 1, 2023
Why Reliance Life Sciences could be the next big thing in India's biotechnology space
Business Today | Rajesh Pherwani | April 8, 2023
Rajesh Pherwani decodes Temasek's majority stake acquisition in Manipal Health Enterprises at a valuation of Rs 40,000 crore
Business Today | Rajesh Pherwani | December 11, 2022
Rajesh Pherwani's outlook for Pharma for the current year
Business Today | Rajesh Pherwani | October 23, 2022
Rajesh Pherwani sharing his views about the potential of pharma CDMO industry
Business Today | Rajesh Pherwani | September 30, 2022
Rajesh Pherwani talks about Syngene's contract research business
Business Today | Rajesh Pherwani | March 31, 2022
Excerpt of Rajesh Pherwani's views, on Alkyl Amines
Economic Times | Rajesh Pherwani | November 11, 2020
Economic Times coverage of Valcreate's leading performance
Economic Times | Rajesh Pherwani | October 13, 2020
Economic Times coverage of Valcreate's leading performance
Economic Times | Rajesh Pherwani | September 23, 2020
Economic Times coverage of Valcreate's leading performance
CNBC TV18 | Rajesh Pherwani | September 23, 2020
CNBC TV18's coverage of Valcreate's leading performance
Business Standard | Rajesh Pherwani | September 12, 2020
Business Standard's coverage of Valcreate's leading performance
CNBC TV18 | Rajesh Pherwani | August 11, 2020
Rajesh Pherwani discusses the TINA factor causing strong upmove in pharma companies in the context of covid world.
CNBC TV18 | Rajesh Pherwani | August 11, 2020
Rajesh Pherwani discusses the TINA factor causing strong upmove in pharma companies in the context of covid world.
Business Standard | Rajesh Pherwani | July 14, 2020
Business Standard's coverage of Valcreate's leading performance
Economic Times | Rajesh Pherwani | July 14, 2020
Economic Times coverage of Valcreate's leading performance
Economic Times | Rajesh Pherwani | June 13, 2020
Economic Times coverage of Valcreate's leading performance
PMS Bazaar | Rajesh Pherwani | June 13, 2020
PMS Bazaar's coverage of Valcreate's leading performance
CNBC TV18 | Rajesh Pherwani | April 24, 2020
Rajesh Pherwani talks about US generic pharma and financials.
CNBC TV18 | Rajesh Pherwani | October 22, 2019
Rajesh Pherwani, founder and portfolio manager of Valcreate Investment Managers in an interview with CNBC-TV18 said that stocks caught in a state of flux offer good value for investors.
CNBC TV18 | Rajesh Pherwani | July 17, 2019
CNBC TV18's coverage of Valcreate's leading performance
Business Today | Rajesh Pherwani | June 28, 2019
Rajesh Pherwani talks about the strong outlook for the Indian economy
CNBC TV18 | Rajesh Pherwani | June 18, 2019
Founder & Portfolio Manager, Valcreate Investment Managers, says expect small & midcaps to do better in the next 5 years; Positive on midcap road construction cos & not looking at telecom space currently.
CNBC TV18 | Rajesh Pherwani | June 17, 2019
The banking sector is likely to report good numbers this earnings season, said Rajesh Pherwani, founder and portfolio manager at Valcreate Investment Managers, adding that DCB bank's poor performance was one of the exceptions.